Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced the successful conclusion of meetings with the U.S. Food and Drug Administration (FDA) that have outlined a clinical path toward registration for SNX-5422 in neuroendocrine tumors (NETs)
October 4, 2018
· 2 min read
